In 1970, the pioneering neuroscientist Julius Axelrod shared the Nobel Prize in Physiology or Medicine with Sir Bernard Katz and Ulf von Euler "for their discoveries concerning the humoral transmitters in the nerve terminals and the mechanism for their storage, release and inactivation." Axelrod's third of the prize was awarded for his studies establishing that norepinephrine-the neurotransmitter of sympathetic nerves and of many neurons in the brain-has its actions terminated through reuptake by the nerve endings that released it into the synapse (the space between the nerve ending and adjacent neurons). Inactivation of a neurotransmitter through its reuptake turned out to be the major mode of inactivation for other biogenic amines such as serotonin and for amino acid neurotransmitters, which together are the principal neurotransmitters in the brain. The three 1961 papers that describe Axelrod's discovery reflect a seminal event in understanding how neurotransmitters work and set the stage for the development of antidepressants such as Prozac (which blocks the reuptake of serotonin).
The concept of chemical neurotransmission began at the turn of the twentieth century with the discovery of the catecholamine epinephrine (also called adrenalin), the hormone of the adrenal medulla responsible for the fight or flight response (Dale, 1960) . In 1899, Lewandowsky first reported that the effects of stimulating sympathetic nerves resembled influences produced by injecting animals with extracts of the adrenal gland. Soon thereafter John Jacob Abel, who founded the Pharmacology Department at the Johns Hopkins Medical School, isolated the active principle of the adrenal medulla and named it epinephrine. T.R. Elliott in Cambridge, England showed that the effects of epinephrine administration closely resembled those from stimulating sympathetic nerves. On May 21, 1904, at a meeting of the Physiological Society, Elliott proposed "a mechanism developed out of the muscle cell, in response to its union with the synapsing sympathetic fibre, the function of which is to receive and transform the nervous impulse. Adrenalin might then be the chemical stimulant liberated on each occasion when the impulse arrives at the periphery." Elliott's proposal was extraordinarily prescient. A century ago most students of the nervous system assumed that electrical activity of a nerve simply "jumped the gap" to the adjacent nerve or organ. To conceptualize chemical neurotransmission and to propose a specific chemical transmitter that was almost exactly correct reflects extraordinary acumen. Elliott's colleagues were skeptical, as epinephrine did not perfectly reproduce the effects of sympathetic nerve stimulation. In 1946, Ulf von Euler isolated the related chemical norepinephrine from sympathetic nerves and established it as the principal neurotransmitter of the sympathetic nervous system (epinephrine and norepinephrine differ by a single N-methyl group and exert very similar effects).
A more glamorous demonstration of chemical neurotransmission is credited to Otto von Loewi for his 1921 experiment in which he stimulated the vagus nerve that innervates heart muscle to slow the rate of the heart beat and then applied the fluid bathing the heart to an independent unstimulated heart whose rate in turn slowed. Pinning down the identity of the neurotransmitter for the vagus nerve (acetylcholine) was less of a challenge than identifying norepinephrine as the principal neurotransmitter of the sympathetic nervous system because acetylcholine had already been characterized. Loewi together with Sir Henry Dale showed that acetylcholine's actions closely corresponded to the results obtained when the vagus nerve was stimulated directly, resulting in their award of the 1936 Nobel Prize for Physiology or Medicine.
Inactivation of acetylcholine in the synapse was quickly shown to be due to the well-characterized enzyme acetylcholinesterase, and blocking the activity of acetylcholinesterase was shown to potentiate neurotransmission by acetylcholine.
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The historic discovery that the catecholamine neurotransmitters of the sympathetic nervous system, norepinephrine and epinephrine, are inactivated through their reuptake by presynaptic nerve terminals provided new insights into neurotransmitter action and paved the way for the development of modern antidepressant drugs.
In this Essay, Solomon Snyder introduces a trio of pioneering neuroscience papers from 1961 by Julius Axelrod and points out what we can learn from the scientific accomplishments of the past.
As acetylcholine was the first neurotransmitter to be identified and characterized, it became axiomatic that for a chemical to be designated a neurotransmitter there must exist a specific enzyme for its inactivation. Norepinephrine in the brain and the sympathetic nervous system was found to be degraded by the enzyme monoamine oxidase and, by the mid1950s, monoamine oxidase inhibitors had been developed as the first antidepressant drugs. But none of these drugs potentiated neurotransmission in the sympathetic nervous system, and monoamine oxidase did not seem to account for all norepinephrine degradation. Enter Axelrod in 1957 with his first major discovery: the identification of the enzyme catechol-O-methyltransferase (COMT), which adds a methyl group to the meta position of norepinephrine or of any other catechol structure (Axelrod, 1957) . Surprisingly, inhibitors of COMT also failed to potentiate sympathetic neurotransmission. Thus, neither of the two enzymes that were known to degrade norepinephrine could explain its inactivation in the sympathetic nervous system.
How did Axelrod discover the reuptake mode of synaptic inactivation for norepinephrine? Seymour Kety, Director of the National Institute of Mental Health's Laboratory of Clinical Science where Axelrod worked, had been tantalized by reports that abnormal oxidation products of epinephrine, such as adrenochrome, were uniquely concentrated in the urine of patients with schizophrenia. 3 H]-epinephrine into cats and rodents, the radiolabel persisted unchanged for several hours in organs rich in sympathetic nerves such as the heart, spleen, and salivary gland. In a critical experiment proposed by Georg Hertting, a visiting scientist, Axelrod and Hertting directly tested the possibility that norepinephrine is taken up by sympathetic nerves (Hertting et al., 1961a; Hertting and Axelrod, 1961) . They removed the superior cervical ganglia of cats unilaterally leading to degeneration of the sympathetic nerves to the salivary gland and eye muscles and showed that [ 3 H]-norepinephrine accumulation was abolished in the denervated side. They then demonstrated that stimulation of the sympathetic nerves on the other side released the radiolabel into the endogenous norepinephrine pool. To my mind the clincher experiments establishing that reuptake inactivates norepinephrine came from Axelrod's drug studies (see Figure 1) . Cocaine was known to potentiate sympathetic neurotransmission, and Axelrod showed that administering cocaine before injecting [ 3 H]-norepinephrine vastly reduced its uptake into the heart, whereas giving the drug after administering [ 3 H]-norepinephrine had no effect (Hertting et al., 1961b) . By contrast, tyramine, which releases norepinephrine from presynaptic nerve terminals, reduced the concentration of the radiolabel in the heart to the same extent whether given before or after [ 3 H]-norepinephrine. In the same series of studies, Axelrod showed that the first major tricyclic antidepressant, imipramine, blocked [
3 H]-norepinephrine uptake . In these experiments, it was not possible to examine the brain directly as the blood-brain barrier precluded entry of the radiolabeled catecholamine into brain tissue. Subsequently, Axelrod and Jacques Glowinski used intraventricular injections of [ 3 H]-norepinephrine to show that clinically effective (but not ineffective) antidepressants blocked norepinephrine accumulation into brain tissue (Glowinski and Axelrod, 1964) . Within a few years, it was established that serotonin is also inactivated by a reuptake process similar to that for the catecholamines. There followed decades of debate as to whether the relief of the clinical symptoms of depression stemmed from inhibition of the uptake of norepinephrine or of serotonin. With the development of drugs Norepinephrine is the key neurotransmitter in the sympathetic nervous system. In a trio of 1961 papers, Julius Axelrod showed that norepinephrine is inactivated through its reuptake into sympathetic nerve terminals. He subsequently showed that blockade of reuptake by drugs such as cocaine or the antidepressant imipramine potentiated norepinephrine activity in the sympathetic nervous system. Figure adapted from Axelrod's Nobel oration (Axelrod, 1971). selective for inhibition of the uptake of one or the other neurotransmitter, we now know that both neurotransmitters are important in depression.
All of Axelrod's key experiments delineating the inactivation of norepinephrine through its reuptake were done in a small laboratory at the National Institutes of Health with two or three colleagues. They were completed within the span of 1 to 2 years, with three key papers appearing in Science and Nature in 1961. At the same time that he was carrying out these landmark studies, Axelrod also was busy identifying the enzymes necessary for production of melatonin, leading soon thereafter to his demonstration of its role as a major hormone of the pineal gland.
Often overlooked are the tools that make great scientific discoveries possible. It should be remembered that radiolabeled chemicals from commercial sources only became readily available to biomedical researchers in the late 1950s. Axelrod's breakthroughs would not have been possible without these substances. Besides the importance of [ 3 H]-catecholamines, a radiolabeled version of S-adenosylmethionine enabled Axelrod to discover several major methylating enzymes that are important in neurotransmitter metabolism. Besides COMT and the melatoninforming enzyme (which methylates N-acetylserotonin), he discovered the histamine-methylating enzyme as well as phenylethanolamine-N-methyltransferase (PNMT), the enzyme that methylates norepinephrine to form epinephrine.
In the late 1960s and early 1970s, amino acid neurotransmitters such as γ-aminobutyric acid (GABA) and glutamate were established, quantitatively speaking, as the major neurotransmitters in the brain. GABA is the principal inhibitory neurotransmitter of the brain and glutamate is the major excitatory neurotransmitter; glycine serves as an inhibitory neurotransmitter in the spinal cord/ lower brain stem. All of these amino acid neurotransmitters owe their synaptic inactivation primarily to reuptake by the presynaptic nerve terminals. The transporter proteins that are responsible for reuptake of the biogenic amines and amino acid neurotransmitters are now well characterized.
Although Axelrod's Nobel prize was awarded for elucidating the inactivation of neurotransmitters by reuptake, this was only a small part of his many contributions to science.
He identified what is now known as the cytochrome p450 family of drugmetabolizing enzymes and discovered melatonin as the hormone of the pineal gland, to cite but a few of his other innovations. Having begun his scientific life as a laboratory technician, finally earning a PhD when he was 43 years old, Axelrod worked directly at the lab bench well past retirement age and still visited his lab at the NIH into his nineties. He remained scientifically active until his sudden death in December 2004 at age 92.
